Member Info for Laura2022

This should help PYC gauge the scope and size of the potential (up to £6mln) of this val201 deal

( see VAL RNS Dec 2024 and PYC Feb 2021)

Pj666

Posts: 193

Price: 0.775

No Opinion

RE: ValToday 10:25

Spoke to Mark last week and he's hoping to reveal the yet un named nasdaq Co.in a blog this week

Also a new IP formulation to extend 201

PJ

How is it worrying ?

Staff /consultants change all the time

Due imminently if you watch the recent interview s

£1.7mln market cap is no where near reflective of the company

KingHomerJ

Posted in: PYC

Posts: 1,677

Price: 0.75

No Opinion

Dosing Application Potential8 Aug 2024 17:03

As I’ve mentioned the potential is significant.

The current dosing application is being developed for Prostate Cancer…..with the precision dosing of Docetaxel which is a chemotherapy….

Docetaxel is a chemotherapy medication used to treat several types of cancer, including breast cancer, head and neck cancer, stomach cancer, prostate cancer, and non-small-cell lung cancer. It's also sold under the brand name Taxotere.

Docetaxel is predominantly used for prostate cancer and the tool is being developed for that however this maybe able to support other types of cancer moving forward…..route to market via Dosemerx

The precision application will save time in favour of the patient and hopefully help overall survival.

Naturally saving time and dosing will save significant amounts of money…

Docetaxel market size was valued at USD 114.78 billion in 2023 and it is estimated to reach USD 252.46 billion in 2032.

The scope for using this software is £££$$

It's game changing

Fantastic news and a lot more to come

This is game changer

The whole of AIM was devastating pate 2023 /2025..that includes ftse 350 (hence why something like TIG hit 70p in early Dec but had takeover yesterday for £1.25

AIM and FTSE 350 were hit , but thankfully the real dross is de listing of getting the boot leaving proper companies left to prosper

PYC should be much much higher than £1.5mln

The crazy thing about AIM is SCGLis £30mln cap with no product or revenue!! GST is £40mln yet FAB only £7mln and PYC £1.5

The Macd and other indicators are oversold again so won't take much to break this 0.8p/0.85p range

People also bought TIG in early December when I said it was undervalued at 75p

Now 125p takeover

:)

Becoming a tempting price

Feels same as buying TIG at 70-80p and now 125p takeover

This looks far too cheap , the seller looks to be clearing fast last 2 weeks

Very good read about how using A.I / mathematical modelling is absolutely a necessity for 3 reasons

1) historic drug failure rate last 20yrs

2) huge cost for Phase 1-III trials

3) FDA mandate as of 2023/24 for all drugs to have been "modelled" before approval

https://www.pharmavoice.com/news/pharma-biotech-pipeline-genmab-jnj-patent-market/718247/

Interesting thread on SAR board

This one stood out as being highly relevant to PYC

fearg

Posts: 940

Price: 24.00

No Opinion

RE: 1801Today 19:06

I'd imagine that AI is used by pharma companies more and more to research areas like toxicity and most likely in indications conditions with most likely positive outcomes. Expect the BOD are utilising all methods available to progress 1801 and 1802.

Yes

But sushi is a liar and was NOT in 6mths ago to enjoy this rise , he was caught in the recent TRP.placing

Anyway

Good wishes

Another 1mln buy today also

Still expecting 50%+ profit like i got on TIG which i was buying 6 weeks ago

Note the price of 0.7p

Please stop lying and making a fool of yourself Santa and friend

Laura2022

Posts: 6,820

Price: 0.70

No Opinion

RE: Twken punt31 Dec 2024 08:56

My buys shown as sells earlier today

No sushi

I am not here but TRP has 27 billion shares in issue and IS NOT up 280%

Deal with this shocking racism on a public forum

Yes newuncle

Only stumbled the other day

Going to filter and ignore

Best way

Hi Humpa

Another one (avocet) with strange posting history since 2015 and for the filter bin